Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.24875/AIDSRev.M20000030 http://scihub22266oqcxt.onion/10.24875/AIDSRev.M20000030 32412509!�!32412509 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32412509.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       AIDS+Rev 2020 ; 22 (2): 63-77 Nephropedia Template TP {{tp|p=32412509|t=2020. COVID-19 Comes 40 Years After AIDS - Any Lesson?|pdf=|usr=}}{{32412509}} gab.com Text COVID-19 Comes 40 Years After AIDS - Any Lesson JO: AIDS Rev http://www.kidney.de/pget.php?&tw=1&pmid=32412509 #FOAvip The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being "with" rather than "by" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic. Twit Text FOAVip COVID-19 Comes 40 Years After AIDS - Any Lesson ????AIDS Rev http://www.kidney.de/pget.php?&tw=1&pmid=32412509 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32412509 #FOAvip English Wikipedia <ref>{{Cite pmid|32412509}}</ref> COVID-19 Comes 40 Years After AIDS - Any Lesson? #MMPMID32412509 Soriano V; Barreiro P; Ramos JM; Eiros JM; de Mendoza C AIDS Rev 2020[Jul]; 22 (2): 63-77 PMID32412509show ga The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Diagnostic testing of active and past SARS-CoV-2 infections needs to expand rapidly, ideally using rapid tests. COVID-19 deaths are highly concentrated in the elderly population, with a large proportion of fatalities being "with" rather than "by" SARS-CoV-2 infection. They are often the result of inadequate health care due to overwhelming demands. To date, there is no specific therapy for SARS-CoV-2 infection. Several antivirals are being tested clinically, including remdesivir, at this time the most promising. For others such as lopinavir/ritonavir, neither significant virological nor clinical benefit has been shown. Given the characteristic pulmonary cytokine storm underlying the pathogenic mechanism of severe COVID-19 pneumonia and acute respiratory distress, antiinflammatory agents are being investigated. The benefit of orticosteroids, hydroxychloroquine, etc., is limited. Monoclonal antibodies targeting different pro-inflammatory cytokines, such as tocilizumab, an anti-interleukin 6 agent, are being tried with encouraging results. Ultimately a protective vaccine will be the best response for controlling the COVID-19 pandemic. |Acquired Immunodeficiency Syndrome/*epidemiology[MESH] |Betacoronavirus/genetics/pathogenicity[MESH] |COVID-19[MESH] |Communicable Disease Control[MESH] |Coronavirus Infections/*epidemiology/immunology/therapy/transmission[MESH] |Cytokine Release Syndrome/immunology[MESH] |HIV Infections/epidemiology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*epidemiology/immunology/therapy/transmission[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]COVID-19 Comes 40 Years After AIDS - Any Lesson?(epmc).pdf DeepDyve Pubget Overpricing